Member Info for Hopester

Prior to FDA approval of Parsortix, when hardly a week seemed to pass without publication of a paper describing some novel application of the technology, a research lab reported findings of the 'cluster busting' effects of a readily available medication approved for a common ailment.

They clearly understood the increased metastatic potential of CTC clusters and were seeking approval to use this medication 'off ticket' to disperse clusters.

I would be very surprised if that research was left to wither on the vine.

Does anyone have any information on how this research progressed - or died?

EC

Long before Parsortix had FDA approval and when almost every week brought a novel application for the technology, there was a paper published descrbing the use of an FDA approved drug which was being used 'off ticket' to disperse CTC clusters.

At that time it was clearly understood that CTC clusters increased the metastatic potential of CTCs.

I cannot recall the purpose of the drug being used for this research, however if memory serves it was a low risk and cost, medication.

I wonder what happened to that research project?

Can anyone shed light?

EC

Here is a link to a description of the process which produces a single cell suspension from a solid tissue sample.

Reichard A, Asosingh K. Best Practices for Preparing a Single Cell Suspension from Solid Tissues for Flow Cytometry. Cytometry A. 2019 Feb;95(2):219-226. doi: 10.1002/cyto.a.23690. Epub 2018 Dec 6. PMID: 30523671; PMCID: PMC6375754.

It looks like a well established process.

I read a paper on this , possibly 10 - 15 years ago, back when hardly a week went by without some research lab coming up with a novel application for Parsortix!

All IMHO

Observing a tumour cell on a slide does not mean that it could be easily extracted for further analysis.

There may be more up to date methods of slide preparation than FFPE (happy to be educated on this), but this prep method will alter the viability of the cell.

The liquidising and Parsortix extraction method that I mentioned earlier could deliver viable cells for analysis with very little delay.

It could provide viable tumour cells from a solid tissue sample before any have been released into the bloodstream as CTCs.

I wonder if something like that is being explored.

All IMHO

Many years ago, on this board, there was a report of work being carried out where solid tissue samples were 'blitzed' and the resulting slurry run through a Parsortix instrument to capture any CTCs present.

This was an alternative to physical examination of multiple FFPE slides.

The 'blitzing' process was not detailed (I think it was termed disocciation or similar) but if the technique has been refined over the years, then this would give a much faster sample turnround than slide preparation and examination.

The solid tissue slurry would contain all of the vital biomarkers as well as CTCs.

Potentially, solid tissue samples could be processed in hours as part of a workflow to a full profile.

I'm sure it was over 5 years ago that a paper was referenced on this chat that used Parsortix to capture single and clusters of CTCs and suggested that clusters had greater metastatic potential than individual CTCs.

In that paper, it was mentioned that an FDA approved drug developed for some other ailment was being used 'off ticket' with great effect to dismantle or to prevent creation of CTC clusters.

I wonder what happened to that research.

I'm sure it was over 5 years ago that a paper was referenced on this chat that used Parsortix to capture single and clusters of CTCs and suggested that clusters had greater metastatic potential than individual CTCs.

In that paper, it was mentioned that an FDA approved drug developed for some other ailment was being used 'off ticket' with great effect to dismantle or to prevent creation of CTC clusters.

I wonder what happened to that research.

Best wishes to you both, DC.

My children are 50+, but I can remember what you're experiencing like it happened yesterday!

Because Cellsearch was considered the Gold Standard and it's hard to look past that to an upstart technology.

Until the upstart shows you how much information you're missing.

All IMHO

So sad to see this project falter on the home straight.

This technology could have been a game changer and God knows we need some revolutionary treatments in the ongoing battles against cancer.

My hope now is that someone with deep pockets picks this up and hurries it over the line. There are desperate people waiting for treatments like this.

It will be interesting to see if this technology can be brought into operation with a few expensive tweaks, or if there is some fundamental, insurmountable issue that has not been divulged to investors.

It's been an interesting but costly ride. Adios AVO!

That is my understanding miavoce and the reason for my question a couple of days ago.

Parsortix harvests the cells and then a downstream assay determines the HER2 status - sequential processes. The laboratory accreditation should supply the validation necessary to apply results to determine the treatment regime.

However, as another posted MBC is probably the most prolific form of cancer so, sadly, no shortage of patients.

Parsortix may also have a role to play with solid biopsy samples - I remember an RNS a number of years ago where a research department was having success with a process whereby solid samples were, I think the term was dissociated,(think blender or smoothie maker!) and the resultant slurry was then run through a Parsortix cassette, apparently with great success. This had the potential to short circuit the normal process of preparing and examining a number of microscope slides to detect CTCs using fallible human eyes.

Let's hope that Parsortix can play a vital role in what could be a game changer with AZNs new treatment.

All IMHO

That

Would I be right in thinking that since Enhertu is tumour agnostic and the only information required for successful treatment is the tumour HER2 status, that Parsortix could be applied to CTC detection in all cancer types?

Suggins
I'm writing that one down!
Lmao

My two buys this morning showing as sells.
Definitely boot filling time at these prices. All IMHO

An enlightening post Bermuda. Thanks.
Just a couple of things I may not have made clear.
I wasn't having a go at the BOD - it was the comment "anyone can buy a piece of the pie" that I pointed out that PIs also had to work tirelessly to earn the dosh to invest in the pie.
By lack of activity, I was referring to the SP activity and it's disconnect from progress and positive news.
I should have made myself clearer.
All IMHO

Reference my last:
For II, read PI.

Dibs.
'Why bother with a long term partnership'?
Would you think any partnership would be exclusive?
It seems to me that Parsortix would potentially disrupt some of Abbot's (or any other partner) existing business and the rate of any developments would be tempered with a view to minimising damage elsewhere in their organisation. At the same time, there would be no incentive to grow the SP and a temptation to wear down IIs prior to making an offer to buy out.
Multiple partnerships would introduce an element of competition and move things forward much more rapidly and give the participating companies a much clearer idea of the value of Angle.
BOJO Excellent post, but I would disagree with your statement that while anyone can buy a piece of the pie, the BOD work tirelessly.
Working tirelessly is how most IIs make the money to invest here (unless you've won the lottery or turned over a Post Office) .

The seeming, current lack of activity can be exasperating for investors, but keep in mind that people are dying who could potentially have had their lives saved or extended if this technique was more generally adopted.
All IMHO

Faicj.
I've been in here for over twelve years and although I've had a few topups at these rock bottom prices, I'm still well under water.
My late wife would have benefitted (as would most cancer sufferers) from PBT and that was my principle reason for investing - just such a shame it has taken so long to get here.
If I can get some of my money back and a working machine then I'll be more than happy.
If you're looking for a dabble and a punt, Galileo Resources will provide guaranteed excitement!
DYOR and all IMHO

A very unpolished presentation Meldrew.
When someone says 'ehm' every second or third word, you can't help forming the impression that they're making it up as they go along or just not altogether sure what they're talking about.
After all of the slipped deadlines and ambiguous time scales I would have expected to hear a brisk, confident statement to reassure nervous investors.
All IMHO